Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29994158 | 1.00 | SLC6A4 (0.52) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL12377872 | 0.85 | SLC6A4 (0.48) | SLC6A4HTR6ATMIDO1 | |
| Indole SCHEMBL733982 | 0.84 | IMPDH2 (0.55) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL13323651 | 0.81 | HTR6 (0.63) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL20846158 | 0.79 | HTR6 (0.51) | SLC6A4HTR6SLC6A2SLC6A3 | |
| SCHEMBL20561892 | 0.78 | HTR6 (0.50) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL14142175 | 0.78 | AR (0.51) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL22359655 | 0.78 | SLC6A4 (0.49) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL3627983 | 0.78 | MAP3K14 (0.54) | SLC6A4HTR6SLC6A2SLC6A3HTR1A | |
| SCHEMBL401146 | 0.78 | DRD2 (0.49) | SLC6A4HTR6SLC6A2SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021018194-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
| EP-3730489-A1 | HETEROARYL COMPOUNDS AS AGROCHEMICAL FUNGICIDES | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| WO-2019057660-A1 | INDOLE AND AZAINDOLE COMPOUNDS WITH SUBSTITUTED 6-MEMBERED ARYL AND HETEROARYL RINGS AS AGROCHEMICAL FUNGICIDES | BASF SE (DE) | 2019-03-28 | — | — | WO | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| CN-101516844-A | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| EP-2044016-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | PFIZER LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| WO-2008009415-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | SLC6A4 4744/4885HTR6 1959/4885SLC6A2 4733/4885 |
| US-20090054459-A1 | Substituted indoles | TPH2, TPH1, HTR1A | SLC6A4 20/4885HTR6 8/4885SLC6A2 30/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | SLC6A4 4729/4885HTR6 1822/4885SLC6A2 4689/4885 |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | SLC6A4 3759/4885HTR6 2850/4885SLC6A2 3995/4885 |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | ADRB2, ADRB1, ADRA2C | SLC6A4 1574/4885HTR6 243/4885SLC6A2 811/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | SLC6A4 3759/4885HTR6 2850/4885SLC6A2 3995/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | SLC6A4 4619/4885HTR6 2305/4885SLC6A2 4652/4885 |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | ADRB2, ADRB1, ADRA2C | SLC6A4 1146/4885HTR6 992/4885SLC6A2 166/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | SLC6A4 4610/4885HTR6 3495/4885SLC6A2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.